5-chloromethyl-1-trityl-1H-benzo[d]imidazole | 168830-92-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 5-chloromethyl-1-trityl-1H-benzo[d]imidazole
• 英文别名: 5-(Chloromethyl)-1-(triphenylmethyl)-1H-benzimidazole；5-(chloromethyl)-1-tritylbenzimidazole
• CAS: 168830-92-0
• 化学式: C₂₇H₂₁ClN₂
• 分子量: 408.93
• InChiKey: KFYBNFKRHZJAGU-UHFFFAOYSA-N

物化性质

• 沸点：
  601.7±65.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-chloromethyl-1-trityl-1H-benzo[d]imidazole 在 palladium on activated charcoal sodium azide 、 氢气 作用下， 以 甲醚 、 N,N-二甲基甲酰胺 为溶剂， 生成 (1-Tritylbenzimidazol-5-yl)methanamine
  参考文献：
  名称：

  Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues

  摘要：

  Peptidomimetic inhibitors of thrombin lacking the important Ser195-carbonyl interaction have been prepared. The binding energy lost after the removal of the activated carbonyl was recaptured through a series of modifications of the PI residues of the bicyclic lactam inhibitors. Selected substituted compounds displayed useful pharmacological profiles both in vitro and in vivo. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00661-8
• 作为产物：
  描述：

  1H-苯并咪唑-5-羧酸 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 氯化亚砜 、 TEA 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 5-chloromethyl-1-trityl-1H-benzo[d]imidazole
  参考文献：
  名称：

  Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues

  摘要：

  Peptidomimetic inhibitors of thrombin lacking the important Ser195-carbonyl interaction have been prepared. The binding energy lost after the removal of the activated carbonyl was recaptured through a series of modifications of the PI residues of the bicyclic lactam inhibitors. Selected substituted compounds displayed useful pharmacological profiles both in vitro and in vivo. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00661-8

文献信息

• NOVEL CARBAMATE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0747355A1

  公开（公告）日：1996-12-11

  Carbamate derivatives represented by the general formula (I), salts thereof, hydrates thereof or solvates thereof wherein each symbol has the following meaning: A ring: a benzene ring or a pyridine ring, B ring: a nitrogen-containing saturated hetero-ring which may have a substituent on the nitrogen atom and which may have a cross-linking, R1: a phenyl group which may have a substituent, a cycloalkyl or cycloalkenyl group having 3 to 8 carbon atoms or a five- or six-membered nitrogen-containing heterocyclic group, X: a single bond or a methylene group, Y: a single bond, a carbonyl group, a methylene group which may be substituted with a hydroxyl group or a group represented by the formula -S(O)ℓ-, and ℓ: an integer of 0, 1 or 2. They have muscarinic M3 receptor antagonism and are useful as an agent for the prevention and treatment of gastrointestinal diseases, respiratory diseases or urinary diseases.

  通式(I)代表的氨基甲酸酯衍生物、其盐类、水合物或溶剂 其中各符号含义如下： A 环：苯环或吡啶环、 B 环：含氮饱和杂环，其氮原子上可有取代基，并可有交联、 R1：可能具有取代基的苯基、具有 3 至 8 个碳原子的环烷基或环烯基或五元或六元含氮杂环基、 X：单键或亚甲基、 Y：单键、羰基、可被羟基或式 -S(O)ℓ- 所代表的基团取代的亚甲基，以及 ℓ：0、1 或 2 的整数。 它们具有毒蕈碱 M3 受体拮抗作用，可用作预防和治疗胃肠道疾病、呼吸系统疾病或泌尿系统疾病的药物。
• Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues
  作者：Sophie Lévesque、Yves St-Denis、Benoit Bachand、Patrice Préville、Lorraine Leblond、Peter D Winocour、Jeremy J Edmunds、J.R Rubin、M.Arshad Siddiqui

  DOI：10.1016/s0960-894x(01)00661-8

  日期：2001.12

  Peptidomimetic inhibitors of thrombin lacking the important Ser195-carbonyl interaction have been prepared. The binding energy lost after the removal of the activated carbonyl was recaptured through a series of modifications of the PI residues of the bicyclic lactam inhibitors. Selected substituted compounds displayed useful pharmacological profiles both in vitro and in vivo. (C) 2001 Elsevier Science Ltd. All rights reserved.